1	The risk and risk factors of chikungunya virus infection and rheumatological
2	sequelae in a cohort of U.S. Military Health System beneficiaries: implications
3	for the vaccine era
4	
5	Pollett SD <sup>1,2*</sup> , Hsieh H-C <sup>1,2</sup> , Lu D <sup>1,2</sup> , Grance M <sup>1,2</sup> , Nowak G <sup>3</sup> , Lanteri C <sup>1</sup> , Tribble D <sup>1</sup> , Burgess TH <sup>1</sup>
6	
7	<sup>1</sup> Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics,
8	Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America
9	<sup>2</sup> Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland,
10	United States of America
11	<sup>3</sup> EpiData Center, Navy and Marine Corps Public Health Center, Portsmouth, Virginia, United States of
12	America
13	
1 4	
14 15	* Corresponding author
15	Email: <u>spollett@idcrp.org</u>
16	

# 18 Abstract

19	Background: Understanding the risk of chikungunya virus (CHIKV) infection and rheumatic sequelae
20	across populations, including travelers and the military, is critical. We leveraged the electronic medical
21	records of about 9.5 million U.S. Military Health System (MHS) beneficiaries to identify the risk of post-
22	CHIKV rheumatic sequelae. Methodology/Principal Findings: MHS beneficiary CHIKV infections
23	diagnosed 2014–2018 were identified from the Disease Reporting System internet, TRICARE Encounter
24	Data Non-Institutional, and Comprehensive Ambulatory/Professional Encounter Record systems. Non-
25	CHIKV controls were matched (1:4) by age, gender, beneficiary status, and encounter date. The
26	frequency of comorbidities and incident rheumatic diagnoses through 2020 were derived from
27	International Classification of Diseases codes and compared between cases and controls. Logistic
28	regression models estimated the association of CHIKV infection with rheumatic sequelae and risk factors
29	for post-CHIKV sequelae. 195 CHIKV cases were diagnosed between July 2014 and December 2018. The
30	mean age was 42 years, and 43.6% were active duty. 63/195 (32.3%) of CHIKV cases had an incident
31	rheumatic diagnosis, including arthralgia, polyarthritis, polymyalgia rheumatica, and/or rheumatoid
32	arthritis, compared to 156/780 (20.0%) of controls (p < 0.001). CHIKV infection remained associated with
33	rheumatic sequelae (aOR = $1.911$ , p = $0.002$ ) after adjusting for prior rheumatic disease and
34	demography. Those with rheumatic CHIKV sequelae had a median 7 healthcare encounters (IQR 3–15).
35	Among CHIKV infections, we found no association between post-CHIKV rheumatic sequelae and
36	demography, service characteristics, or comorbidities. Conclusions/Significance: CHIKV infection is
37	uncommon but associated with rheumatic sequelae among MHS beneficiaries, with substantial
38	healthcare requirements in a proportion of cases with such sequelae. No demographic, clinical, or
39	occupational variables were associated with post-CHIKV rheumatic sequelae, suggesting that prediction
40	of these complications is challenging in MHS beneficiaries. These findings are important context for
41	future CHIKV vaccine decision making in this and other populations.

# 42 Author summary:

43	We examined U.S. Military Health System (MHS) electronic medical records during to identify the
44	likelihood of rheumatic complications after chikungunya virus (CHIKV) infection. Overall, CHIKV
45	infections were rare in the MHS, with 195 cases found in the records between 2014 and 2018 (a period
46	which encompassed the peak of the CHIKV epidemic in the Americas). Of these, about 32% received a
47	rheumatic diagnosis after infection, including arthralgia, polyarthritis, polymyalgia rheumatica, and
48	rheumatoid arthritis. Patients who had a rheumatic diagnosis had on average 7 healthcare encounters
49	for their post-CHIKV rheumatic complication, and a quarter had more than 15 healthcare encounters.
50	We did not find any demographic, clinical, or occupational characteristics associated with developing
51	rheumatic complications after CHIKV, suggesting that predicting rheumatic complications from CHIKV
52	may be challenging in MHS beneficiaries. These findings may provide important context for decisions
53	about implementing an approved chikungunya vaccine to military servicemembers and other MHS
54	beneficiaries.

55

## 56 Introduction

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus belonging to the *Togaviridae* family [1]. The
ecology of CHIKV is characterized by a sylvatic cycle involving non-human primates and arboreal *Aedes*species and urban human-to-human transmission cycles involving the *A. aegypti* and *A. albopictus*vectors [1]. While CHIKV is defined by a single serotype, multiple genotypes have evolved with global
geographic expansion including the Asian and descendant Asian-Caribbean lineages, and
East/Central/South African and Indian Ocean lineages [1-3].

The 2013–2015 neotropical epidemic in the Americas involved over 1.6 million suspected or confirmed CHIKV cases [4]. While cases rapidly declined after the initial neotropical pandemic, there is an ongoing substantive CHIKV burden in the Americas in addition to ongoing circulation in Africa [5, 6] and Asia [7, 8]. Recently, the Pan American Health Organization issued an alert indicating the geographic range of CHIKV has expanded in the Americas, with notable resurgence in certain regions of Latin America [9-11].

70 Acute CHIKV infection illness is characterized by a high symptomatic-to-asymptomatic ratio, with clinical 71 features including an abrupt onset of high fever, polyarthralgia, backache, headache, and fatigue [12]. 72 Atypical acute CHIKV illness manifestations (e.g., acute encephalitis) are rare, potentially severe, and 73 more often occur in the extremes of age and in those with underlying comorbidities [12-17]. Diagnosis 74 of CHIKV infection relies on blood polymerase chain reaction (PCR) within the first week of illness and 75 serology thereafter [18]. Management of acute CHIKV is generally supportive, with fluid replacement, 76 analgesia and avoidance of non-steroidal anti-inflammatory drugs until dengue has been excluded as a 77 differential diagnosis [19]. There are no current vaccines or other preventive medical countermeasures 78 available for CHIKV aside from avoidance of vectors in endemic transmission regions [19]. Advanced 79 vaccine development has been challenging due to the unpredictable nature of CHIKV outbreaks [20]. 80 However, CHIKV vaccine U.S. Food and Drug Administration licensure may soon occur using a serological 81 correlate of protection [21].

82

The rheumatological manifestations of CHIKV may be categorized by timing and clinical phenotype [22]. Acute CHIKV arthralgia is frequently reported and mostly occurs in mostly peripheral joints with a symmetrical pattern, although large joints can be affected [22]. Joint swelling and synovitis often accompanies this acute polyarthralgia; functional impairment during this acute phase is common due debilitating pain [22]. Chronic rheumatological manifestations typically involve the joints affected in

88	acute CHIKV arthralgia [22]. Estimates on the frequency of persistent post-acute manifestations
89	(predominantly arthralgia or arthritis) vary significantly, with metanalysis estimates as high as 43% at 3
90	months, 21% at 12 months, and 14% at 18 months after initial CHIKV illness onset [22-24]. This
91	heterogeneity is believed to reflect differences in study populations and methodologies. Pathogenesis
92	studies have indicated that persistent host inflammation, rather than persistent synovial viral
93	replication, plays a key role in post-CHIKV arthralgia [25, 26]. There is currently a wide variation in
94	clinical management for chronic post-CHIKV sequelae [15] but post-acute CHIKV arthropathy is severe
95	enough in some to warrant the use of biological or disease-modifying antirheumatic drugs [27].
96	
97	While those residing in CHIKV endemic regions experience the highest burden of this arbovirus, travelers
98	and the deploying military are also significant stakeholders for understanding the risk of CHIKV infection
99	and post-CHIKV sequelae. There is limited published data on the burden of CHIKV in U.S. Military Health
100	System (MHS) beneficiaries [28, 29] and none define the risk and risk factors of post-acute CHIKV
101	sequelae in this population. Understanding the risk and risk factors of CHIKV and CHIKV sequelae is
102	important for clinical prognostication and may support cost-effectiveness analyses for vaccine policy
103	with potential future licensed vaccines; such findings may be generalizable to traveler populations also.
104	
105	The objectives in this study were to describe to characterize incident CHIKV cases that were diagnosed in
106	the MHS between 2014–2018 and to further describe the risk and risk factors of acute and chronic post-
107	CHIKV rheumatological sequelae in such CHIKV cases, compared to matched controls. Here, we
108	leveraged a virtual cohort derived from over 9.5 million MHS beneficiaries, with follow-up through 2020.
109	

# 110 Methods

# Population, setting and identification of CHIKV cases and matched controls

113

114 The MHS serves approximately 9.5 million beneficiaries, including active duty servicemembers, retirees

- and dependents. This includes care delivered within the United States, U.S. Territories (including Puerto
- 116 Rico, Guam, and the U.S. Virgin Islands), and in beneficiaries located other countries.
- 117
- 118 For this study, we identified deduplicated unique CHIKV cases in MHS beneficiaries via multiple data
- streams from 2005 through 2018, including: (i) clinical microbiology lab (serology and PCR) results from
- 120 Disease Reporting System internet (DRSi)/EpiData Center, (ii) International Classification of Diseases,
- 121 10th Revision (ICD-10) code A92.0 CHIKV disease entries from TRICARE Encounter Data Non-Institutional
- 122 (TEDNI), and (iii) ICD-10 code A92.0 CHIKV disease from Comprehensive Ambulatory/Professional
- 123 Encounter Record (CAPER). The treatment locations of cases were inferred by clinical provider ZIP code.
- 124 To estimate the risk of post-CHIKV rheumatological sequalae, CHIKV negative MHS beneficiary controls
- were matched (1:4) with cases by age group, gender, date of healthcare encounter (+/-1 month), and
- 126 beneficiary status at the time of matching healthcare encounter. Controls were randomly selected
- 127 within these matching strata.
- 128

# Demographic, post-CHIKV diagnosis and comorbidity data abstraction from the electronic medical record

131 Demographic ICD-9 and ICD-10 code data abstracted from cases and controls (using Armed Forces

- 132 Health Longitudinal Technology Application (AHLTA) and the Composite Health Care System (CHCS). The
- 133 sequelae of interest were any rheumatologic disorders (See S1 Table for ICD-9 and ICD-10 codes). Co-
- 134 morbidity was defined as a condition/disorder (including rheumatological) which pre-existed before the
- time of the first CHIKV infection diagnosis (or first matched healthcare encounter of the time-matched

136	control. We defined post-CHIKV rheumatological complications as new post-CHIKV rheumatological
137	diagnoses with a first onset at or after the first CHIKV diagnosis (or the healthcare encounter used for
138	matching for controls without CHIKV). When a pre-CHIKV rheumatological and post-CHIKV
139	rheumatological diagnosis mapped to the same ICD code, we further adjudicated a pre-existing
140	rheumatological diagnoses from a new post-CHIKV complication using DX_DESC-level diagnosis coding
141	(Agency for Healthcare Research and Quality Clinical Classifications Software system code). A similar
142	approach was taken for controls without CHIKV.

143

### 144 Statistical analysis

145 Demographic, clinical, and occupational characteristics of cases and controls were summarized. The

146 frequency of rheumatological sequelae were compared in cases and controls. Conditional logistic

147 regression (on age and sex matched cases and controls) were used to estimate the independent

association between CHIKV infection and short-term (<3 months) versus long-term (≥3 months)

149 complications, adjusting for prior comorbidities (including pre-existing rheumatological comorbidities).

150 Unadjusted and adjusted odds ratios were presented. Finally, among those with CHIKV infections, we

151 performed multinomial regression for any to determine risk factors for any rheumatologic related

152 sequelae. For each multinomial regression analysis, there were 3 comparisons: participants with short-

term (<3 months), long-term ( $\geq$ 3 months) and no sequelae.

154

All p values were two-sided, with an alpha significance threshold of 0.05. Analyses were conducted using
SAS software (version 9.4; SAS).

157

### 158 **Ethical considerations**

- 159 This protocol was reviewed and approved for execution by the IRB of the Uniformed Services University
- 160 of the Health Sciences, Bethesda, Maryland, United States of America.
- 161

## 162 **Results**

- 163 We identified 195 unique CHIKV cases diagnosed in the MHS between July 2014 and December 2018 (S1
- 164 Fig). The most frequent locations of clinical encounters were in Puerto Rico, Texas, and California, but
- 165 these reflect provider ZIP codes of diagnoses (including potential diagnoses made after deployments or
- 166 other beneficiary travel) and do not necessarily reflect location of where cases acquired CHIKV infections
- 167 (Fig 1). Our finding of the majority of cases being diagnosed in Puerto Rico agreed with prior, smaller
- 168 studies in MHS beneficiaries [29, 30]. Time series of all MHS CHIKV cases (by month) indicated the peak
- 169 of MHS CHIKV cases occurring in late 2014 during the peak year of the Americas CHIKV epidemic.
- 170

#### 171 Fig 1. Location of CHIKV cases by U.S. state or territory.

- 172
- 173 The median age of CHIKV cases was 42 years (IQR 31–54 years), and 43.6% were active duty
- servicemembers (Table 1). Compared to age, gender, beneficiary status, and healthcare encounter-
- 175 matched controls, cases differed from controls with respect to race (p < 0.001). Among active duty
- 176 CHIKV cases, we noted that Army service and enlisted rank were most frequent; the frequency of these
- 177 categories were more common than matched controls (p < 0.001; Table 1). CHIKV cases had a higher
- 178 frequency of all measured comorbidities compared to age, sex, and beneficiary-matched controls (p <
- 179 0.001; Table 2).
- 180

#### 181 **Table 1. Demographic and professional characteristics in CHIKV cases and controls.**

CHIKV negative			
 controls <sup>ª</sup>	CHIKV cases	Total	p value <sup>b</sup>

No. of subjects (N)	780	195	975	
Characteristic	n (n/N %)	n (n/N %)	n (n/N %)	
Gender				>.9999
Male	412 (52.82)	103 (52.82)	515 (52.82)	
Female	368 (47.18)	92 (47.18)	460 (47.18)	
<b>Age,</b> median, [Q1–Q3]	41 [29–56]	42 [31–54]	41 [30–55]	0.6026
\ge				>.9999
≤25	84 (10.77)	21 (10.77)	105 (10.77)	
26–35	204 (26.15)	51 (26.15)	255 (26.15)	
36–45	190 (24.36)	48 (24.62)	238 (24.41)	
46–64	204 (26.15)	51 (26.15)	255 (26.15)	
65+	98 (12.56)	24 (12.31)	122 (12.51)	
Race				<.0001
White	321 (41.15)	113 (57.95)	434 (44.51)	
Black	55 (7.05)	12 (6.15)	67 (6.87)	
Asian or Pacific Islander	23 (2.95)	12 (6.15)	35 (3.59)	
Other	21 (2.69)	30 (15.38)	51 (5.23)	
Unknown	360 (46.15)	28 (14.36)	388 (39.79)	
Beneficiary				>.9999
Active duty	340 (43.59)	85 (43.59)	425 (43.59)	
Dependent	108 (13.85)	27 (13.85)	135 (13.85)	
Retiree	80 (10.26)	20 (10.26)	100 (10.26)	
Others	252 (32.31)	63 (32.31)	315 (32.31)	
Service branch <sup>c</sup>				<.0001
Air Force	189 (24.23)	8 (4.10)	197 (20.21)	
Army	76 (9.74)	51 (26.15)	127 (13.03)	
Coast Guard	8 (1.03)	23 (11.79)	31 (3.18)	
Other	67 (8.59)	3 (1.54)	70 (7.18)	
Not applicable	440 (56.41)	110 (56.41)	550 (56.41)	

Rank				<.0001
Enlisted	233 (29.87)	69 (35.38)	302 (30.97)	
Officer	107 (13.72)	16 (8.21)	123 (12.62)	
Not applicable	440 (56.41)	110 (56.41)	550 (56.41)	

<sup>a</sup>Controls were matched with cases by age group, gender, beneficiary and date of encounter (+/- 1 month).

183 <sup>b</sup>p-values are calculated from a Chi-squared/Fisher's exact test or Kruskal-Wallis test, as appropriate.

<sup>c</sup>Service branch and rank are only available for active duty. Other non-active duty subjects are grouped under "Not
 applicable" category.

186

#### 187 Table 2. Comorbidities in CHIKV cases and controls.

	СНІК-	CHIK+	Total	p value <sup>ª</sup>
Total # of subjects	780	195	975	
Comorbidities (ICD diagnoses before time of matching)				
None	461 (59.10)	34 (17.44)	495 (50.77)	<.0001
Cancer	30 (3.85)	22 (11.28)	52 (5.33)	<.0001
Cardiovascular disease	196 (25.13)	95 (48.72)	291 (29.85)	<.0001
Chronic respiratory disease	91 (11.67)	58 (29.74)	149 (15.28)	<.0001
Mental health condition	117 (15.00)	72 (36.92)	189 (19.38)	<.0001
Osteoporosis	26 (3.33)	19 (9.74)	45 (4.62)	0.0001
Jpper gastrointestinal disease	103 (13.21)	75 (38.46)	178 (18.26)	<.0001
Neurologic disease	122 (15.64)	80 (41.03)	202 (20.72)	<.0001
Rheumatologic disease	117 (15.00)	84 (43.08)	201 (20.62)	<.0001
Osteoarthritis	92 (11.79)	55 (28.21)	147 (15.08)	<.0001
Other non-traumatic joint disorders	29 (3.72)	32 (16.41)	61 (6.26)	<.0001
Rheumatoid arthritis and related disease	12 (1.54)	17 (8.72)	29 (2.97)	<.0001
pondylosis; disc disorders; other back problems	51 (6.54)	37 (18.97)	88 (9.03)	<.0001

<sup>a</sup>p values were calculated from a Chi-squared/Fisher's exact test.

#### 189

190	We noted 63/195	(32.3%) of CHIKV	cases had an incident post-CHIKV	rheumatological diagnosis,
-----	-----------------	------------------	----------------------------------	----------------------------

191 compared to 156/780 (20.0%) of controls (p = 0.0002) (Table 3). Osteoarthritis, rheumatoid arthritis and

192 related diagnoses (including inflammatory polyarthropathy), and non-traumatic joint disorder associated

193 categories (including unspecified arthropathy, polyarthralgia and polyarthritis) were noted with

194 statistically significant higher frequency in post-CHIKV cases versus controls (Table 3, S2 Table).

195

#### **Table 3. Rheumatological sequelae in CHIKV cases and controls.**

	СНІК-	CHIK+	Total	p value <sup>®</sup>
No. of subjects	780	195	975	
Any rheumatic sequelae <sup>b</sup>	156 (20.00)	63 (32.31)	219 (22.46)	0.0002
Rheumatic sequelae by category <sup>c</sup>				
Infective arthritis and osteomyelitis	0 (0.00)	1 (0.51)	1 (0.10)	0.2000
Malaise and fatigue	59 (7.56)	18 (9.23)	77 (7.90)	0.4402
Osteoarthritis	2 (0.26)	4 (2.05)	6 (0.62)	0.0166
Other connective tissue disease	12 (1.54)	4 (2.05)	16 (1.64)	0.5404
Other non-traumatic joint disorders	17 (2.18)	21 (10.77)	38 (3.90)	<.0001
Other screening for suspected conditions	81 (10.38)	24 (12.31)	105 (10.77)	0.4384
Rheumatoid arthritis and related disease	2 (0.26)	7 (3.59)	9 (0.92)	0.0003

<sup>a</sup>p values were calculated from a Chi-squared/Fisher's exact test.

198 <sup>b</sup>Subject with more than one diagnosis code were only counted once.

<sup>1</sup>99 <sup>c</sup>CCS\_DX\_DESC category, subject may have multiple diagnosis with different categories.

200

201 Compared to controls, CHIKV infection was associated with post-infection rheumatological diagnoses

202 (aOR = 1.91, 95% Cl 1.272–2.870, p = 0.0018) after adjusting for prior the presence of any prior pre-

203 CHIKV rheumatological diagnoses, beneficiary status, age, sex, and race (Table 4). The magnitude of this

204	effect size was larger when the outcome was stratified into short-term ( $\leq$ 3 month) post-CHIKV
205	rheumatological diagnoses versus long-term (diagnosis recurred beyond 3 months post-CHIKV infection)
206	rheumatic sequelae (aOR = 6.41, p < 0.001 short-term sequelae; aOR = 1.43, p = 0.09 long-term
207	sequelae, respectively) (Table 5). Those with post-CHIKV rheumatological sequelae had a median 7
208	healthcare encounters for rheumatological diagnoses (IQR 3–15, range 1–33) through the period of
209	observation.

210

# Table 4. Unadjusted and adjusted odds ratio of CHIKV infection on rheumatic-related sequelae (n = 975).

	Unadjusted				Adjusted <sup>®</sup>			
	OR	95 9	% CI	p value	OR	95% CI		p value
CHIK positive	1.909	1.348	2.703	0.0003	1.911	1.272	2.870	0.0018
Rheumatic related comorbidity	1.609	1.134	2.283	0.0078	1.137	0.763	1.695	0.5283
Age	1.011	1.002	1.019	0.0107	1.012	1.002	1.022	0.0181
Male	0.984	0.728	1.330	0.9171	0.918	0.620	1.358	0.6669
Race (ref: White)								
Black	1.062	0.580	1.944	0.8464	1.178	0.633	2.192	0.6055
Asian or Pacific Islander	0.846	0.359	1.995	0.7024	0.758	0.314	1.830	0.3551
Other	0.960	0.698	1.319	0.8001	1.294	0.846	1.977	0.2307
Beneficiary (ref: active duty)								
Dependents of active duty	0.591	0.353	0.990	0.0458	a	•		
Retirees	0.752	0.435	1.301	0.3084	a 			
Others	1.056	0.752	1.483	0.7541	a —			
Service branch (ref: Air Force)								
Army	2.088	1.266	3.444	0.0039	1.582	0.930	2.691	0.0004
Coast Guard	0.564	0.187	1.702	0.3092	0.360	0.113	1.143	0.1017
Other	0.709	0.342	1.472	0.3565	0.686	0.328	1.437	0.7368

Not applicable (non-active duty)	1.039	0.697	1.550	0.8501	0.640	0.379	1.080	0.4056
Rank (ref: enlisted)						•		
Officer	1.600	0.996	2.571	0.0518	a 			
Not applicable (non-active duty)	1.016	0.721	1.431	0.9287	a —			

<sup>a</sup>Beneficiary and rank are not included in the adjusted model due to collinearity with service branch.

```
214
```

#### Table 5. Adjusted odds ratio on rheumatic-related short-term and long-term sequelae (n = 975).

_	Short-term (<3 month)			Long-term (≥3 month)				
	OR	959	% CI	p value	OR	95%	% CI	p value
CHIK positive	6.410	2.904	14.152	<.0001	1.428	0.947	2.153	0.0894
Rheumatic-related comorbidity	0.616	0.242	1.567	0.3087	1.329	0.878	2.012	0.1789
Age	1.018	0.997	1.040	0.0991	1.008	0.998	1.018	0.0989
Male	1.053	0.469	2.365	0.9011	1.071	0.731	1.569	0.7247
Race (ref: white)								
Black	1.118	0.238	5.243	0.8593	1.093	0.573	2.085	0.5557
Asian or Pacific Islander	1.614	0.336	7.748	0.6634	0.702	0.261	1.882	0.4449
Other	1.314	0.542	3.186	0.8761	1.002	0.668	1.501	0.7193

216 Note: 1) "No Rheumatic related sequelae" is consider as reference group for the outcome variable. 2) "Service" is

excluded from the adjusted model due to quasi-complete separation of data points.

218

219 Among those with CHIKV infections, we found no association between post-CHIKV rheumatic sequelae

and age, sex, race, active-duty status, or pre-existing comorbidities. Non-Army service branch and

female sex was associated with a reduced odds of post-CHIKV rheumatological sequelae, but this was

222 not statistically significant (Table 6).

223

Table 6. Unadjusted and adjusted odds ratio on rheumatic-related sequelae among people with CHIK infection (n = 195).

-		Unad	justed	ed Adjusted				
	OR	95%	6 CI	p value	OR	95% CI		p value
Age	1.002	0.985	1.020	0.8156	1.006	0.978	1.034	0.6969
Male (ref: female)	0.974	0.534	1.777	0.9323	0.679	0.288	1.599	0.3751
Race (ref: white)								_
Black	0.685	0.175	2.680	0.5865	0.624	0.138	2.816	0.4970
Asian or Pacific Islander	1.467	0.436	4.935	0.5356	1.350	0.376	4.853	0.4577
Other	0.924	0.468	1.826	0.8208	0.866	0.397	1.888	0.8440
Service branch (ref: Army)								
Coast Guard	0.256	0.076	0.860	0.0276	0.275	0.077	0.979	0.0917
Other	1.461	0.395	5.407	0.5703	1.566	0.406	6.042	0.0634
Not applicable (non- active duty)	0.457	0.228	0.913	0.0266	0.341	0.141	0.828	0.0922
Comorbidities								_
Cancer	0.975	0.376	2.526	0.9586	1.029	0.324	3.269	0.9618
Cardiovascular disease	0.937	0.514	1.709	0.8320	0.799	0.371	1.720	0.5659
Chronic respiratory disease	1.431	0.751	2.725	0.2757	1.902	0.841	4.300	0.1226
Mental health condition	0.974	0.523	1.815	0.9339	0.889	0.420	1.881	0.7575
Osteoporosis	1.250	0.467	3.346	0.6569	1.488	0.390	5.680	0.5609
Upper gastrointestinal disease	0.977	0.527	1.812	0.9422	0.988	0.482	2.024	0.9737
Neurologic disease	0.757	0.408	1.403	0.3762	0.657	0.300	1.439	0.2941
Rheumatologic	1.086	0.593	1.988	0.7899	0.985	0.472	2.059	0.9688

226 *Note:* Service branch was regrouped to avoid quasi-complete separation. Other includes: Air Force and others.

## 227

# 228 Conclusion

229 Understanding the risk of CHIKV infection and complications in deploying U.S. military servicemembers

and other MHS beneficiaries is important, particularly with upcoming possible CHIKV vaccine licensure.

231	We found a very low number of CHIKV cases identified in the MHS, despite this study period covering
232	the peak CHIKV epidemic in the Americas and leveraging data from about 9.5 million beneficiaries. Our
233	findings correlate with low number of CHIKV infections in other U.S. MHS studies, although such studies
234	were either smaller, earlier in the CHIKV epidemic and/or less comprehensive in their use of electronic
235	medical record (eMR) data sources [28, 31]. Additionally, our findings correlate with a recent post-
236	deployment serology study of 1500 deployments to South America and Puerto Rico with a low post-
237	deployment seropositivity rate of 1.7% (highest in those serving in Puerto Rico) [32]. Our findings further
238	agree with studies in other armed forces which also note a low frequency of CHIKV infections [28].
239	
240	These low frequencies of infection may be attributed to effective personal mosquito avoidance or
241	heterogeneity in risk exposure (for example, based on deployment role) when deployed or activated in
242	CHIKV endemic countries or territories. Among CHIKV infections in servicemembers, we noted higher
243	frequency Army service and enlisted ranks compared to matched servicemember controls without
244	CHIKV; these groups have previously been noted at higher risk for other arboviruses [33, 34]. While the
245	location of diagnosis may not reflect where the infection was acquired, the highest number of cases
246	were diagnosed in Puerto Rico is consistent with the known high transmission of CHIKV during the
247	neotropical epidemic [35].
248	
249	While the overall number of infections was very low, we found a substantive risk of post-CHIKV

rheumatological complications. We noted a considerable burden of disease with a median 7 healthcare
encounters for this complication, and 25% of these complicated CHIKV cases required between 15 and
33 further encounters through the period of observation. These findings highlight that, while CHIKV
infections are overall rare in MHS beneficiaries, patient morbidity in complicated CHIKV cases can be
substantial, as noted in non-MHS studies [22].

256	The overall low number of CHIKV infections limited statistical power for examining risk factors for post-
257	CHIKV sequelae. We found a non-statistically significant trend toward Army and male sex having a
258	higher risk of rheumatic complications, but no other predictors were noted, including pre-existing
259	comorbidities. Further study of cumulative CHIKV infections in MHS-based virtual cohorts over time may
260	identify clearer risk factors for this complication, and this may assist in more precise prognostication of
261	CHIKV cases in the MHS. As this study comprises the largest number of CHIKV infections in any military
262	study, we would conclude that prediction of MHS CHIKV cases may progress to complicated
263	rheumatological sequelae remains challenging, underscoring the need for optimal prevention of CHIKV
264	infection.
265	
266	There were several strengths to this study. The use of the MHS includes a substantive number of
267	beneficiaries who deploy or are stationed in CHIKV endemic regions and allowed for long term follow-up
268	of cases to determine longer term complications. We derived CHIKV cases from a range of eMR data
269	sources, including clinical microbiology laboratory results, to identify more infections than prior MHS-
270	based studies [28-31]. Our study limitations included the use of ICD codes to diagnose CHIKV and post-
271	CHIKV complications; prior evaluations of CHIKV ICD diagnosis coding have noted imperfect specificity
272	[31] and this study was unable to perform chart adjudications. Conversely, CHIKV diagnoses may have
273	been missed in some clinical presentations, and not all cases may have presented to care (including
274	during deployments).
275	
276	Future directions include further studies which could also examine for non-rheumatological CHIKV
277	sequelae such as neurocognitive complications, mood, and long-term functional impact (for example,
278	[36, 37]). Finally, studies could leverage sera routinely collected from the U.S. military servicemembers

and used for arboviral research (i.e., the Department of Defense Ser	a Repositor	v  32-34	<ol> <li>to identify</li> </ol>
--	-------------	----------	---------------------------------

- 280 prognostic and treatment related biomarkers for those beneficiaries with persistent post-CHIKV
- 281 sequelae, as well as enabling ongoing serosurveillance of the risk and risk factors of CHIKV in deployed
- 282 military, particularly during an era of increasing CHIKV risk in the Americas [9].
- 283

## 284 **Disclaimer**

- 285 The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect
- the views, opinions, or policies of Uniformed Services University of the Health Sciences; the Department
- of Defense; the Departments of the Army, Navy, or Air Force; the Defense Health Agency; the National
- 288 Institutes of Health, the Department of Health and Human Services or the Henry M. Jackson Foundation
- for the Advancement of Military Medicine, Inc. Mention of trade names, commercial products, or
- 290 organizations does not imply endorsement by the U.S. government. The investigators have adhered to
- the policies for protection of human subjects as prescribed in 45 CFR 46.
- 292

## 293 Funding statement

294 The protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of

- 295 Defense program executed by the Uniformed Services University of the Health Sciences through a
- 296 cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine,
- 297 Inc.. This project has been funded in part by the National Institute of Allergy and Infectious Diseases at
- the National Institutes of Health, under an interagency agreement (Y1-AI-5072); and the Military
- 299 Infectious Diseases Research Program. The authors declare no conflicts of interest.

300

### 301 **References**

- 302 1. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a
- 303 vaccine. Expert Rev Vaccines. 2012;11(9): 1087-1101. pmid:23151166
- 304 2. Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral
- 305 Res. 2015;120: 32-39. pmid:25979669
- 306 3. Rezza G, Weaver SC. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease
- impact and hurdles to vaccine development. PLoS Negl Trop Dis. 2019;13(1): e0006919.
- 308 pmid:30653504
- 309 4. 54th Directing Council. Report on chikungunya virus transmission and its impact in the region of the
- Americas. 67th Session of the Regional Committee of WHO for the Americas; September 28 to
- 311 October 2, 2015; Washington, DC: Pan American Health Organization and World Health
- 312 Organization Regional Office for the Americas. Available from:
- 313 https://www3.paho.org/hq/dmdocuments/2015/CD54-INF-3-e.pdf
- 5. Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of
- dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-
- 316 71. pmid:36200059
- 317 6. Asaga Mac P, Airiohuodion PE, Yako AB, Makpo JK, Kroeger A. The seroprevalence and hidden
- burden of chikungunya endemicity and malaria mono- and coinfection in Nigeria. Int J Environ Res
- 319 Public Health. 2022;19(15): 8896. pmid:35897268
- 320 7. Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The global
- 321 epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the
- development and introduction of vaccines. PLoS Negl Trop Dis. 2022;16(1): e0010069.
- 323 pmid:35020717

- 8. Pan American Health Organization, World Health Organization. Cases of chikungunya virus disease.
- 325 2023. Available from: https://www3.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-
- 326 weekly-en.html
- 9. Centers for Disease Control and Prevention. Increased chikungunya virus activity in Paraguay and
- 328 associated risk to travelers. 2023. Available from:
- 329 https://emergency.cdc.gov/han/2023/han00487.asp
- 10. Pan American Health Organization, World Health Organization. Epidemiological alert: Chikungunya
- increase in the region of the Americas. 2023. Available from:
- 332 <u>https://www.paho.org/en/documents/epidemiological-alert-chikungunya-increase-region-americas</u>
- 11. Pan American Health Organization, World Health Organization. Epidemiological alert: Increase in
- cases and deaths from chikungunya in the region of the Americas. 2023. Available from:
- 335 <u>https://www.paho.org/en/documents/epidemiological-alert-increase-cases-and-deaths-</u>
- 336 <u>chikungunya-region-americas</u>
- 12. Centers for Disease Control and Prevention. Clinical evaluation and disease. 2023. Available from:
- 338 https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html
- 13. de Morais Alves Barbosa Oliveira R, Kalline de Almeida Barreto F, Praça Pinto G, Timbó Queiroz I,
- 340 Montenegro de Carvalho Araújo F, Wanderley Lopes K, et al. Chikungunya death risk factors in
- 341 Brazil, in 2017: A case-control study. PLoS One. 2022;17(4): e0260939. pmid:35389992
- 14. Sharp TM, Keating MK, Shieh WJ, Bhatnagar J, Bollweg BC, Levine R, et al. Clinical characteristics,
- histopathology, and tissue immunolocalization of chikungunya virus antigen in fatal cases. Clin
- 344 Infect Dis. 2021;73(2): e345-e354. pmid:32615591
- 15. Webb E, Michelen M, Rigby I, Dagens A, Dahmash D, Cheng V, et al. An evaluation of global
- 346 Chikungunya clinical management guidelines: A systematic review. EClinicalMedicine. 2022;54:
- 347 101672. pmid:36193172

- 16. Pescarini JM, Rodrigues M, Paixão ES, Cardim L, Brito CAA, Costa MDCN, et al. Dengue, Zika, and
- chikungunya viral circulation and hospitalization rates in Brazil from 2014 to 2019: An ecological
- 350 study. PLoS Negl Trop Dis. 2022;16(7): e0010602. pmid:35895718
- 17. Chee YS, Ahamad Fouzi N, Chong YM, Sam IC, Chan YF, Chua CL, et al. Chikungunya encephalopathy
- and pneumonia in a young infant presenting with septic shock. J Paediatr Child Health. 2022;58(8):
- 353 1468-1471. pmid:35175651
- 18. Centers for Disease Control and Prevention. Diagnostic testing. 2023. Available from:
- 355 <u>https://www.cdc.gov/chikungunya/hc/diagnostic.html</u>
- 19. Centers for Disease Control and Prevention. Treatment and Prevention. 2023. Available from:
- 357 https://www.cdc.gov/chikungunya/hc/treatment-prevention.html
- 20. Tran QM, Soda J, Siraj A, Moore S, Clapham H, Perkins TA. Expected endpoints from future
- 359 chikungunya vaccine trial sites informed by serological data and modeling. Vaccine. 2023;41(1):
- 360 182-192. pmid:36424258
- 361 21. Hills S. Overview of chikungunya and chikungunya vaccines. Meeting of the Advisory Committee on
- 362 Immunization Practices (ACIP); October 19-20, 2022; Atlanta, Georgia: Centers for Disease Control
- 363 and Prevention.
- Suhrbier A. Rheumatic manifestations of chikungunya: Emerging concepts and interventions. Nat
   Rev Rheumatol. 2019;15(10): 597-611. pmid:31481759
- 366 23. Rodríguez-Morales AJ, Cardona-Ospina JA, Urbano-Garzón SF, Hurtado-Zapata JS. Prevalence of
- 367 post-chikungunya infection chronic inflammatory arthritis: A systematic review and meta-analysis.
- 368 Arthritis Care Res (Hoboken). 2016;68(12): 1849-1858. pmid:27015439
- 369 24. Paixão ES, Rodrigues LC, Costa MDCN, Itaparica M, Barreto F, Gerardin P, et al. Chikungunya chronic
- disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;112(7): 301-316.
- 371 pmid:30007303

- 372 25. Sengupta S, Bhattacharya N, Tripathi A. Increased CRP, anti-CCP antibody, IL-2R, COMP levels in
- 373 prognosis of post-chikungunya chronic arthritis and protective role of their specific genotypes
- against arthritic manifestation. Virus Res. 2022;323: 198998. pmid:36356677
- 26. Dobbs JE, Tritsch SR, Encinales L, Cadena A, Suchowiecki K, Simon G, et al. Regulatory T-cells and
- 376 GARP expression are decreased in exercise-associated chikungunya viral arthritis flares. Front
- 377 Immunol. 2022;13: 1007106. pmid:36275717
- 378 27. Ranzolin A, Marques CDL, da Rocha Junior LF, Duarte ALBP, de Lima HD, de Almeida Martins LM, et
- al. Treatment with biological therapy is associated with faster recovery and lower frequency of
- treatment switch among rheumatic patients with chikungunya fever. Adv Rheumatol. 2022;62(1):
- 381 44. pmid:36376923
- Frickmann H, Herchenröder O. Chikungunya virus infections in military deployments in tropical
   settings—a narrative minireview. Viruses. 2019;11(6): 550. pmid:31197085
- 384 29. Writer JV, Hurt L. Chikungunya infection in DoD healthcare beneficiaries following the 2013
- introduction of the virus into the Western Hemisphere, 1 January 2014 to 28 February 2015.
- 386 MSMR. 2015;22(10): 2-6. pmid:26505074
- 387 30. O'Donnell FL, Stahlman S, Fan M. Surveillance for vector-borne diseases among active and reserve
   388 component service members, U.S. Armed Forces, 2010-2016. MSMR. 2018;25(2): 8-15.
- 389 pmid:29485891
- 390 31. Wellington T, Fraser JA, Kuo HC, Hickey PW, Lindholm DA. The burden of arboviral infections in the
- 391 Military Health System 2012-2019. Am J Trop Med Hyg. 2023;108(5): 1007-1013. pmid:37037439
- 392 32. Pollett S, Lanteri C, Forshey B, Trefry S, Winkelmann E, Nasar F, et al. Serosurveillance of
- chikungunya infections among U.S. military personnel deploying in the Americas, 2013-2020.
- ASTMH 71st Annual Meeting; October 30 to November 3, 2022; Seattle, Washington: American
- 395 Society of Tropical Medicine and Hygiene. Available from:

396		https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-
397		Meeting-Abstract-Book.pdf
398	33.	Pollett S, Kuklis CH, Barvir DA, Jarman RG, Romaine RM, Forshey BM, et al. The seroepidemiology of
399		dengue in a US military population based in Puerto Rico during the early phase of the Zika
400		pandemic. PLoS Negl Trop Dis. 2022;16(1): e0009986. pmid:35061659
401	34.	Hesse EM, Martinez LJ, Jarman RG, Lyons AG, Eckels KH, De La Barrera RA, et al. Dengue virus
402		exposures among deployed U.S. military personnel. Am J Trop Med Hyg. 2017;96(5): 1222-1226.
403		pmid:28193746
404	35.	Sharp TM, Roth NM, Torres J, Ryff KR, Pérez Rodríguez NM, Mercado C, et al. Chikungunya cases
405		identified through passive surveillance and household investigations—Puerto Rico, May 5-August
406		12, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(48): 1121-1128. pmid:25474032
407	36.	Peixoto VGMNP, Azevedo JP, Luz KG, Almondes KM. Cognitive dysfunction of chikungunya virus
408		infection in older adults. Front Psychiatry. 2022;13: 823218. pmid:35449568
409	37.	Doran C, Elsinga J, Fokkema A, Berenschot K, Gerstenbluth I, Duits A, et al. Long-term chikungunya
410		sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curacao. PLoS
411		Negl Trop Dis. 2022;16(3): e0010142. pmid:35231033
412		
413	Su	pporting information

- 414 S1 Fig. Chikungunya virus case identification from U.S. Military Health System electronic medical
- 415 record systems. TEDNI–TRICARE Encounter Data Non-Institutional; CAPER–Comprehensive
- 416 Ambulatory/Professional Encounter Record.

- 418 S1 Table. International Classification of Diseases, 9th Revision (ICD-9) and ICD-10 codes (including
- 419 cross-walked ICD-9 codes) used to identify rheumatological healthcare encounters in cases and
   420 controls.

- 422 S2 Table. Long description of rheumatological healthcare encounters by chikungunya virus (CHIKV)
- 423 infection status.

Fig 1.

